Alabama compounder slapped with FDA warning letter

FDA sign

Eagle Pharmacy, an Alabama drug compounder, was slapped with a warning letter by the FDA for unsanitary conditions and failing to register new compounds.

The letter, which was posted on the FDA’s website, cited the Hoover, AL-based compounder for “serious deficiencies” in its manufacturing process. During an August 2015 inspection, the regulatory agency observed an employee “moving their arm over open vials during aseptic filling.”

The inspector also saw an employee place materials onto a critical work surface without first disinfecting the materials. Additionally, media plates used for personnel and environmental monitoring didn’t contain disinfectant neutralizers, which could potentially bias results.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

The agency also cited Eagle Pharmacy for failing to show correct procedures to ensure its products are produced in a sterile environment, which poses a risk of contamination.

The company was also cited for not having FDA-approved applications for drug products and misbranding its compounded products.

The agency noted in its warning that some of Eagle’s responses to the inspection fell short of FDA regulations and without prompt action the company could face legal action, including seizure of the facility. It said it will re-inspect the site.

Suggested Articles

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.